---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029017"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T00:57:48.853500+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025

## Summary
- Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.
- Cash, cash equivalents and investments ~$1.2B at Dec 31, 2024, down ~$60M from Sept 30, 2024.
- FDA accepted aficamten NDA with target PDUFA date of September 26, 2025; MAA validated in Europe.
- Topline results from Phase 3 MAPLE-HCM trial expected in Q2 2025.
- 2025 GAAP operating expense guidance: $670M-$710M; non-cash stock comp $110M-$120M.

## SEC filing metadata
- accession: 0000950170-25-029017
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/0000950170-25-029017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/cytk-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029017
- JSON: https://secwatch.observer/filing/0000950170-25-029017.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.